outlooktherapeutics.comCrawled Oct 15, 2026
Outlook Therapeutics is bringing LYTENAVA (bevacizumab-vikg) injection, an FDA-approved ophthalmic bevacizumab formulation for neovascular (wet) age-related macular degeneration (nAMD), to retina specialists and their patients.
Faisal G. Sukhtian has served as chairman since 2025 and as a member of Outlook Therapeutics’ Board of Directors since 2017. Faisal G. Sukhtian is executive director at GMS Holdings and oversees investments in its portfolio.
Outlook Therapeutics, Inc. 111 S. Wood Ave Unit #100 Iselin, NJ 08830 609.619.3990 Business development and partnering inquiries To inquire regarding partnership opportunities with Outlook Therapeutics, please contact: info@outlooktherapeutics.com Europe:
Outlook Therapeutics is a late clinical-stage biopharmaceutical company developing and launching an ophthalmic formulation of bevacizumab for retinal indications, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO).
Outlook secures FDA approval for **LYTENAVA**, its VEGF inhibitor formulation of bevacizumab, making it the first and only on-label ophthalmic treatment for wet age-related macular degeneration (AMD). The drug targets retinal vascular leakage and abnormal blood vessel growth in advanced AMD cases. LYTENAVA joins a limited pipeline of approved therapies for this progressive eye disease.
Jul 2026Eyes On EyecareNews article
Outlook Therapeutics secures FDA approval for **LYTENAVA™**, the first ophthalmic formulation of bevacizumab specifically developed for treating **wet age-related macular degeneration (AMD)**. The drug provides a dedicated retinal therapy option, distinct from off-label systemic uses. Wet AMD affects central vision and is a leading cause of irreversible blindness in older adults. LYTENAVA™ is designed for direct ocular administration, addressing unmet needs in retinal care.
Jul 2026GlobeNewswireNews article
Outlook Therapeutics secures FDA approval of its appeal for ONS-5010 (LYTENAVA), a bevacizumab-based treatment for wet age-related macular degeneration (AMD). The company had faced three prior rejections for its new drug application (NDA) before this recent victory. The decision clears a key regulatory hurdle for Outlook’s potential entry into the competitive retinal disease treatment market.
May 2026Eyes On EyecareNews article
The FDA issues a third Complete Response Letter (CRL) for Outlook Therapeutics’ ONS-5010 (LYTENAVA), a treatment for wet age-related macular degeneration (AMD). The agency requests additional confirmatory data before reconsidering approval. Outlook Therapeutics resubmitted the Biologics License Application (BLA) following prior CRLs, delaying potential market entry for the drug.
Jan 2026Pharmacally -News article